Feb. 28 at 11:55 PM
$CRBP
Revenue potential here is what makes this interesting at ~
$100M mkt cap. CRB-701 is a Nectin-4 ADC playing in three massive oncology markets — HNSCC alone is ~
$2.5B today growing to
$6B+ by 2033. Urothelial is ~
$3.5B heading to
$7B+. Cervical adds billions more on top. For context, Padcev — also a Nectin-4 MMAE ADC — is pacing ~
$2B/yr with peak sales est
$2.7-3.4B, and it doesn’t even have an HNSCC indication. CRB-701 is posting 48% ORR there. Piper Sandler PT
$51. On the obesity side, CRB-913 is targeting a TAM that Goldman Sachs and Morgan Stanley project at
$95-150B by 2030-2035. The GLP-1 weight loss drug market alone is ~
$49B by 2030. The kicker — 50-70% of GLP-1 users report nausea. CRB-913 reported zero GI side effects. Even a niche slice of that market is transformational for a company this size. Two multi-billion dollar addressable markets,
$173M cash, and catalysts every quarter through 2026.
